Two Studies Evaluating the Combination of REVLIMID(R) and rituximab in Non ... MarketWatch (press release) Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) , today announced that results from two studies evaluating the combination of REVLIMID(R) (lenalidomide) and rituximab in various non-Hodgkin's lymphomas ... Two Studies Evaluating the Combination of REVLIMID ® and rituximab in Non ... |
